Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995) | Zendy

Peter L. Greenberg | Zendy; Sandra J. Lee | Zendy; Ranjana H. Advani | Zendy; Martin S. Tallman | Zendy; Branimir I. Šikić | Zendy; Louis Letendre | Zendy; Kathleen Dugan | Zendy; Bert L. Lum | Zendy; David L. Chin | Zendy; Gordon W. Dewald | Zendy; Elisabeth Paietta | Zendy; John M. Bennett | Zendy; Jacob M. Rowe | Zendy

Open Access

Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

Author(s) -

Peter L. Greenberg,

Sandra J. Lee,

Ranjana H. Advani,

Martin S. Tallman,

Branimir I. Šikić,

Louis Letendre,

Kathleen Dugan,

Bert L. Lum,

David L. Chin,

Gordon W. Dewald,

Elisabeth Paietta,

John M. Bennett,

Jacob M. Rowe

Publication year - 2004

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2004.07.048

Subject(s) - medicine , mitoxantrone , cytarabine , etoposide , myeloid leukemia , refractory (planetary science) , myelodysplastic syndromes , oncology , chemotherapy , bone marrow , physics , astrobiology

To determine whether adding the multidrug resistance gene-1 (MDR-1) modulator valspodar (PSC 833; Novartis Pharmaceuticals, Hanover, NJ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research